BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 28246237)

  • 1. Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus.
    Young LH; Viscoli CM; Curtis JP; Inzucchi SE; Schwartz GG; Lovejoy AM; Furie KL; Gorman MJ; Conwit R; Abbott JD; Jacoby DL; Kolansky DM; Pfau SE; Ling FS; Kernan WN;
    Circulation; 2017 May; 135(20):1882-1893. PubMed ID: 28246237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone.
    Young LH; Viscoli CM; Schwartz GG; Inzucchi SE; Curtis JP; Gorman MJ; Furie KL; Conwit R; Spatz ES; Lovejoy A; Abbott JD; Jacoby DL; Kolansky DM; Ling FS; Pfau SE; Kernan WN;
    Circulation; 2018 Sep; 138(12):1210-1220. PubMed ID: 29934374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pioglitazone Prevents Stroke in Patients With a Recent Transient Ischemic Attack or Ischemic Stroke: A Planned Secondary Analysis of the IRIS Trial (Insulin Resistance Intervention After Stroke).
    Yaghi S; Furie KL; Viscoli CM; Kamel H; Gorman M; Dearborn J; Young LH; Inzucchi SE; Lovejoy AM; Kasner SE; Conwit R; Kernan WN;
    Circulation; 2018 Jan; 137(5):455-463. PubMed ID: 29084736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pioglitazone Therapy in Patients With Stroke and Prediabetes: A Post Hoc Analysis of the IRIS Randomized Clinical Trial.
    Spence JD; Viscoli CM; Inzucchi SE; Dearborn-Tomazos J; Ford GA; Gorman M; Furie KL; Lovejoy AM; Young LH; Kernan WN;
    JAMA Neurol; 2019 May; 76(5):526-535. PubMed ID: 30734043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.
    Kernan WN; Viscoli CM; Furie KL; Young LH; Inzucchi SE; Gorman M; Guarino PD; Lovejoy AM; Peduzzi PN; Conwit R; Brass LM; Schwartz GG; Adams HP; Berger L; Carolei A; Clark W; Coull B; Ford GA; Kleindorfer D; O'Leary JR; Parsons MW; Ringleb P; Sen S; Spence JD; Tanne D; Wang D; Winder TR;
    N Engl J Med; 2016 Apr; 374(14):1321-31. PubMed ID: 26886418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Pioglitazone Hydrochloride Therapy After Stroke or Transient Ischemic Attack According to Pretreatment Risk for Stroke or Myocardial Infarction.
    Kernan WN; Viscoli CM; Dearborn JL; Kent DM; Conwit R; Fayad P; Furie KL; Gorman M; Guarino PD; Inzucchi SE; Stuart A; Young LH;
    JAMA Neurol; 2017 Nov; 74(11):1319-1327. PubMed ID: 28975241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease.
    Inzucchi SE; Viscoli CM; Young LH; Furie KL; Gorman M; Lovejoy AM; Dagogo-Jack S; Ismail-Beigi F; Korytkowski MT; Pratley RE; Schwartz GG; Kernan WN;
    Diabetes Care; 2016 Oct; 39(10):1684-92. PubMed ID: 27465265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of pioglitazone on cognitive function in patients with a recent ischaemic stroke or TIA: a report from the IRIS trial.
    Furie KL; Viscoli CM; Gorman M; Ford GA; Young LH; Inzucchi SE; Guarino PD; Lovejoy AM; Conwit R; Tanne D; Kernan WN;
    J Neurol Neurosurg Psychiatry; 2018 Jan; 89(1):21-27. PubMed ID: 28939682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial.
    Viscoli CM; Brass LM; Carolei A; Conwit R; Ford GA; Furie KL; Gorman M; Guarino PD; Inzucchi SE; Lovejoy AM; Parsons MW; Peduzzi PN; Ringleb PA; Schwartz GG; Spence JD; Tanne D; Young LH; Kernan WN;
    Am Heart J; 2014 Dec; 168(6):823-9.e6. PubMed ID: 25458644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54.
    Bonaca MP; Wiviott SD; Morrow DA; Steg PG; Hamm C; Bhatt DL; Storey RF; Cohen M; Kuder J; Im K; Magnani G; Budaj A; Nicolau JC; Parkhomenko A; López-Sendón J; Dellborg M; Diaz R; Van de Werf F; Corbalán R; Goudev A; Jensen EC; Johanson P; Braunwald E; Sabatine MS
    J Am Heart Assoc; 2018 Nov; 7(22):e009260. PubMed ID: 30571502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.
    Erdmann E; Dormandy JA; Charbonnel B; Massi-Benedetti M; Moules IK; Skene AM;
    J Am Coll Cardiol; 2007 May; 49(17):1772-80. PubMed ID: 17466227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care).
    Cavender MA; White WB; Jarolim P; Bakris GL; Cushman WC; Kupfer S; Gao Q; Mehta CR; Zannad F; Cannon CP; Morrow DA
    Circulation; 2017 May; 135(20):1911-1921. PubMed ID: 28246236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial.
    Guimarães PO; Leonardi S; Huang Z; Wallentin L; de Werf FV; Aylward PE; Held C; Harrington RA; Moliterno DJ; Armstrong PW; White HD; Alexander KP; Lopes RD; Mahaffey KW; Tricoci P
    Am Heart J; 2018 Feb; 196():28-35. PubMed ID: 29421012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04).
    Wilcox R; Bousser MG; Betteridge DJ; Schernthaner G; Pirags V; Kupfer S; Dormandy J;
    Stroke; 2007 Mar; 38(3):865-73. PubMed ID: 17290029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pioglitazone improves insulin sensitivity among nondiabetic patients with a recent transient ischemic attack or ischemic stroke.
    Kernan WN; Inzucchi SE; Viscoli CM; Brass LM; Bravata DM; Shulman GI; McVeety JC; Horwitz RI
    Stroke; 2003 Jun; 34(6):1431-6. PubMed ID: 12730556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance.
    Spence JD; Viscoli C; Kernan WN; Young LH; Furie K; DeFronzo R; Abdul-Ghani M; Dandona P; Inzucchi SE
    Diabetes Obes Metab; 2022 Jun; 24(6):1150-1158. PubMed ID: 35253334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pioglitazone and Risk for Bone Fracture: Safety Data From a Randomized Clinical Trial.
    Viscoli CM; Inzucchi SE; Young LH; Insogna KL; Conwit R; Furie KL; Gorman M; Kelly MA; Lovejoy AM; Kernan WN;
    J Clin Endocrinol Metab; 2017 Mar; 102(3):914-922. PubMed ID: 27935736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in people with stroke or transient ischaemic attack.
    Liu J; Wang LN
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD010693. PubMed ID: 29197071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in patients with stroke or transient ischaemic attack.
    Liu J; Wang LN
    Cochrane Database Syst Rev; 2015 Oct; (10):CD010693. PubMed ID: 26511368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.